Angiotensin receptor blockers and diuretics as combination therapy: clinical implications

AJH

2004; 17:277–280

Editorial

Angiotensin Receptor Blockers and Diuretics as Combination Therapy: Clinical Implications C. Venkata S. Ram

D

Activation of the RAAS may play a pathogenetic role in hypertension, cardiovascular hypertrophy, large artery

stiffness, and atherogenesis.6,7 Importance of the RAAS in promoting target-organ disease in hypertension is being increasingly recognized and emphasized. The ACEIs and ARBs block the RAAS through different sites of action, but both drug classes demonstrate protective effects on the heart and kidney.8 Unlike ACEIs, which provide incomplete angiotensin II blockade due to alternate pathways of angiotensin II (Ang II) production,9,10 ARBs provide a more complete and specific suppression of the RAAS. The ARBs block the binding of Ang II to the angiotensin type I (AT1) receptor, independent of the pathway of Ang II generation.11 The AT1 receptor blockade results in smooth muscle relaxation; reduction in peripheral vascular resistance, plasma volume, aldosterone secretion and cellular hypertrophy; and increased excretion of water and salt.12,13 Although ARBs block the AT1 receptor site, the angiotensin type 2 (AT2) receptor is still free to bind with Ang II. Preliminary data suggest that AT2 receptor activation mediates vasodilation, cell growth inhibition, apoptosis, and tissue repair, thereby counteracting some of the pathogenic effects precipitated by the binding of Ang II at the AT1 receptor.7,9 Cough and angioedema may be associated with ACEI therapy due to clinical-mediated effects, but ARBs are unlikely to be associated with these adverse events (rare case reports of angioedema have been documented with the ARB losartan). As a result, ARB usage is associated with greater patient compliance. The incidence of adverse events associated with ARBs in clinical studies is generally similar to and not higher than placebo.12,14,15 The ARBs exert an antihypertensive efficacy similar to other drug classes, including ACEIs, CCBs, diuretics, and ␤-blockers, with the added benefit of having superior tolerability.16 In some large-scale studies, ARBs provided remarkable protection against cardiovascular (CV) morbidity and mortality in high-risk patients.3,17–19 As with ACEIs, significant regression of left ventricular hypertrophy has been demonstrated with ARB usage.20 Like ACEIs, ARBs retain their effectiveness in renal insuffi-

Received September 4, 2003. First decision September 4, 2003. Accepted September 4, 2003. From the Texas Blood Pressure Institute, Dallas Nephrology Associates and University of Texas Southwestern Medical Center, Dallas,

Texas. Address correspondence and reprint requests to: Dr. C. Venkata S. Ram, 13154 Coit Road, Suite 100, Dallas, Texas 75240; e-mail: [email protected]

espite the overwhelming evidence that adequate control of blood pressure (BP) significantly reduces cardiovascular morbidity and mortality, only 34% of hypertensive patients in the US have their BP controlled to the recommended goal of ⬍140/90 mm Hg.1 This number falls short of the Healthy People 2010 goal of 50%, and indicates an urgent need for improved antihypertensive therapy. Furthermore, although BP control rates have improved during the past decade, the prevalence of hypertension is increasing. Thus, there is a persistent need for effective implementation of BP control guidelines in the community. Regarding the optimal use of antihypertensive therapy, new guidelines provided recently by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7)1 are in agreement with the recommendations that thiazide-type diuretics should be used as initial therapy in most patients. Thiazide diuretics are efficacious and typically more affordable than most other antihypertensive agents. However, less than 50% of hypertensive patients are able to achieve their BP goal with the use of any monotherapy.2 The JNC 7 has recommended that if BP is ⬎20/10 mm Hg above goal, a second antihypertensive agent from a different drug class should preferably be used in combination with a diuretic. Additional agents include angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), ␤-blockers (BBs), and calcium channel blockers (CCBs). In addition to achieving target BP goals, antihypertensive therapy should also offer prevention against hypertension-associated complications, such as heart failure, stroke, and kidney disease. Agents that block the reninangiotensin-aldosterone system (RAAS), ie, ACEIs and ARBs, are particularly effective at lowering BP and providing cardiovascular and renal protective benefits over and beyond their effects on BP.3–5

RAAS Blockade and ARBs

© 2004 by the American Journal of Hypertension, Ltd. Published by Elsevier Inc.

0895-7061/04/$30.00 doi:10.1016/j.amjhyper.2003.09.002

278

ANGIOTENSIN RECEPTOR, HYPERTENSION, & COMBINATION THERAPY

ciency, and can thus be recommended for possible renoprotection. Clinical trials with ARBs have shown a 20% to 30% reduction in the progression of renal damage in type 2 diabetics with nephropathy.20 The ARBs demonstrate advantageous efficacy and tolerability, and are useful as first-line antihypertensive agents, especially in high-risk individuals. Head-to-head trials show that the newer ARBs— candesartan, cilexetil, irbesartan, and telmisartan— demonstrate significantly better BP reductions than the older ARBs, losartan potassium, and valsartan. Furthermore, olmesartan medoxomil, the newest ARB to be approved, has shown significantly better diastolic BP reductions versus losartan potassium, valsartan, and irbesartan. Olmesartan, like other long-acting ARBs, compares favorably with other antihypertensive agents, such as atenolol, captopril, felodipine, and amlodipine besylate.16 As has been observed with other classes of antihypertensive agents, ARBs as monotherapy generally do not reduce BP to recommended levels in most hypertensive individual,8 hence, combination therapy with a diuretic significantly enhances the BP-lowering potential of ARBs. In this issue, a study by Chrysant et al suggests that olmesartan and hydrochlorothiazide (HCTZ) may be a potent antihypertensive combination.21

ARB/HCTZ Combination Therapy and Hypertension Control An analysis of 17 randomized, controlled clinical trials evaluated the antihypertensive efficacy of losartan potassium, valsartan, irbesartan, and candesartan in combination with HCTZ.22 The combination of these ARBs with 12.5 mg/d (HCTZ) resulted in a reduction in diastolic BP of 9.9 to 13.6 mm Hg and in systolic BP of 16.1 to 20.6 mm Hg. Responder rates were 56% to 70%. In comparison, pooled data from seven placebo-controlled trials designed to evaluate the antihypertensive efficacy of the new ARB, olmesartan monotherapy, showed mean reductions in seated (Se) diastolic BP and Se systolic BP of 12.2 and 15.1 mm Hg, respectively, at the recommended starting dosage of 20 mg/d. At the maximum recommended dosage of 40 mg/d,8,15 olmesartan medoxomil monotherapy showed mean reductions in Se diastolic BP and Se systolic BP of 13.1 and 17.6 mm Hg, respectively. Therefore, olmesartan monotherapy is associated with significant decreases in diastolic BP and systolic BP levels, similar to those observed for other ARBs when used in conjunction with HCTZ. The factorial design clinical study reported by Chrysant et al was the first to evaluate the antihypertensive efficacy of olmesartan in combination with HCTZ.21 This particular study design was chosen because trials of this type are typically used to evaluate whether a specific ARB/HCTZ combination therapy is more efficacious than either of the individual agents used as monotherapies. These trials are not intended to evaluate a dose–response relationship be-

AJH–March 2004 –VOL. 17, NO. 3

tween different dose combinations, but rather are statistically powered to evaluate the safe and effective clinical doses of ARB/HCTZ combination therapy in hypertensive patients. In the Chrysant et al study, a total of 502 patients were randomized to one of 12 groups for 8 weeks of treatment of placebo, olmesartan monotherapy (10, 20, or 40 mg/d), HCTZ monotherapy (12.5 or 25 mg/d), or combination therapy with olmesartan plus HCTZ. Olmesartan plus HCTZ demonstrated a dose-related efficacy across all combinations evaluated that were greater than monotherapy with either agent. The reductions from baseline in mean trough Se diastolic BP/Se systolic BP ranged from 16.4/20.1 mm Hg for the olmesartan 20 mg/HCTZ 12.5 mg combination up to 21.9/26.8 mm Hg for the olmesartan 40 mg/HCTZ 25 mg combination. The responder rate ranged from 77.1% to 81.0% of patients in the olmesartan HCTZ 12.5 mg/d combination groups, and from 89.1% to 92.3% of patients in the olmesartan HCTZ 25.0 mg/d combination groups. Thus, combining olmesartan with a diuretic resulted in significantly greater reductions in systolic BP and diastolic BP than either agent alone. Optimal use of an ARB with a diuretic follows the recommended therapeutic strategy of combining two antihypertensive agents, with complementary mechanisms of action to obtain a greater BP reduction. Combining an ARB with a diuretic has several advantages, including: 1) allowing lower doses of component drugs to be used than would be required to achieve the same efficacy using a single agent, thereby resulting in lower incidence of adverse effects, and improved patient compliance; 2) potentiation of the antihypertensive and hemodynamic response of ARBs, resulting from salt depletion induced by thiazide diuretics; and 3) reducing the risk of diuretic-induced hypokalemia. By virtue of their pharmacologic actions, thiazide diuretics can cause hypokalemia in some patients. In susceptible patients, diuretic-induced hypokalemia can trigger cardiac arrhythmias. Furthermore, it has been proposed that the hypokalemia may predispose patients who have silent myocardial ischemia to potentially fatal arrhythmias.23 Hypokalemia caused by hydrochlorothiazide has also been implicated in the development of rhabdomyolysis.24 The HCTZ-induced hypokalemia has been shown to be less prevalent in clinical studies when HCTZ is combined with an ARB.21,25–27 One explanation for diuretic-induced hypokalemia is activation of the renin-angiotensin-aldosterone axis. The ARBs interrupt the reninaldosterone link normally mediated by Ang II and, therefore, aldosterone-induced urinary potassium loss is attenuated. Recent observations suggest that for patients with diuretic-induced hypokalemia, it may be beneficial to reduce the HCTZ and add an ARB to maintain normal potassium homeostasis. In this way, adequate BP control can be achieved without the risk of hypokalemia associated with the high-dose HCTZ therapy.27

AJH–March 2004 –VOL. 17, NO. 3

ANGIOTENSIN RECEPTOR, HYPERTENSION, & COMBINATION THERAPY

Conclusions There is little doubt that lowering the BP level to any degree in patients with hypertension reduces the risk of stroke and ischemic heart disease. The health benefits are far greater when the BP is normalized. In addition to nonpharmacologic therapy, drug treatment is often necessary to achieve goal BP levels. It is now clearly recognized that adequate BP reduction cannot be achieved with monotherapy. Thus, the current guidelines recommend liberal utilization of combination therapy to achieve desired BP levels. Combination therapy can include the addition of a second agent to an existing monotherapy regimen or the concurrent use of multiple drugs of fixed combination products. Whichever option is used, the dosages should be properly titrated based on the therapeutic response and maintenance of achieved BP levels. Antihypertensive drugs from different pharmacologic classes can be combined to capture effective BP control rates. A common (and often required) component of combination antihypertensive drug therapy is a thiazide diuretic. When a thiazide is added to any nondiuretic antihypertensive drug, one can expect a synergistic, or sometimes an additive, effect on the BP. Hence, antihypertensive combinations, which include a thiazide diuretic, have been widely and successfully used in clinical practice for many decades. This is a well-tested, time-honored strategy. Although the concept of combination therapy is not new, it is only in the recent years that the interest in the approach has resurfaced. Data from large therapeutic and end point trials in hypertension conducted in the past 10 to 15 years has convinced us that to decrease morbidity and mortality in hypertension, a majority of patients require more than one drug, at least two, and in some cases three. Fixed dose combinations that include a diuretic have been available for many years. For example, thiazide/␤-blocker, thiazide/centrally acting agent, and thiazide/ACEI combination formulations have been successfully used in clinical practice. However, it is only recently that fixed dose combinations of long-acting ARBs and diuretics have become available, and are being increasingly used in the management of hypertension with much clinical success. Based on their pharmacodynamic, pharmacokinetic, clinical, and biochemical effects (Table 1), combination of an ARB with a thiazide diuretic yields a significant therapeutic benefit in achieving improved control of hypertension in the community, while providing target organ protection and freedom of side effects, which historically limited the widespread acceptance of previously available combination therapies. Because a large number of patients treated for hypertension continue to have high BP, there is a general agreement to initiate therapy with the combination of two agents from different pharmacologic classes—a strategy recommended by JNC 7 to improve the BP control rates in the community.

279

Table 1. Clinical consequences of ARBs and diuretics

Antihypertensive effects Reninangiotensin system Sympathetic nervous system Potassium balance Uric acid Left ventricular hypertrophy

ARBs

Diuretics

ARBs ⴙ Diuretics

2

2

22

22

1

2

22

1

2

1 2⫽

2 1

⫽ ⫽

22

2⫽

22

References 1.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560 –2572. 2. Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R: Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1995;155:1757–1762. 3. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345: 1667–1675. 4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861– 869. 5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860. 6. Izzo JL Jr: Systolic hypertension, arterial stiffness, and vascular damage role of the renin-angiotensin system. Blood Press Monit 2000;5(Suppl 2):S7–S11. 7. Unger T: The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89:3A–10A. 8. Greathouse M: A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? Congest Heart Fall 2002;8:313–320. 9. Burnier M: Angiotensin II type 1 receptor blockers. Circulation 2001;103:904 –912. 10. Chung O, Csikos T, Unger T: Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens 1999;13(Suppl 1): S11–S20; discussion S33–S34. 11. Birkenhager WH, de Leeuw PW: Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999;17:873–881. 12. Israili ZH: Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14(Suppl 1): S73–S86.

280

ANGIOTENSIN RECEPTOR, HYPERTENSION, & COMBINATION THERAPY

13. Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 20 1996;334:1649 –1654. 14. Grossman E, Messerli FH, Neutel JM: Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 10 2000;160:1905–1911. 15. Neutel JM: Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 19 2001;87:37C–43C. 16. Smith DH: Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade. Am J Hypertens 2002; 15:108S–114S. 17. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 6 2000;355:1582–1587. 18. Dickstein K, Kjekshus J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 7 2002;360:752–760. 19. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 23 2002;359:995–1003.

AJH–March 2004 –VOL. 17, NO. 3

20. Kaplan NM: Kaplan’s Clinical Hypertension, 8th ed. Philadelphia, Lippincott Williams & Wilkins, 2002. 21. Chrysant SG, Weber MA, Wang AC, Hinman DJ : Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252–259. 22. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM: Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418 –426. 23. Cohen JD: Abnormal electrocardiograms and cardiovascular risk: role of silent myocardial ischemia. Evidence from MRFIT. Am J Cardiol 1992;70:14F–18F. 24. Girola SS, Mazzone A, Moroni M, Porta C, Nastasi G, Notario A: Hypokalemic rhabdomyolysis and thiazide diuretics. 3 clinical cases. Ann Ital Med Int 1995;10:134 –137. 25. Langtry HD, McClellan KJ: Valsartan/hydrochlorothiazide. Drugs 1999;57:751–758. 26. Wellington K, Faulds DM: Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002;62:1983–2005. 27. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y: Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12:861–866.